Drug Issues in Dialysis Patients: Study Finds High Rates of Interactions and Adverse Reactions

What is it about?

The study conducted a prospective cross-sectional analysis in the Haemodialysis Centres of two hospitals in Azad Kashmir to assess drug-related problems (DRPs) among haemodialysis patients. It evaluated various DRPs such as drug interactions, adverse effects, and treatment failures through univariable logistic regression. The study identified that 76.7% of patients experienced DRPs, with phosphate binders being the primary source, followed by antihypertensive medicines and PPIs/antacids. A total of 228 DRPs were documented in 150 patients, with drug interactions and adverse drug reactions being the most common. The study found that polypharmacy and comorbid conditions significantly increased the odds of DRPs in these patients. It highlighted the complexity of drug regimens in haemodialysis patients and the necessity for regular monitoring to manage DRPs effectively.

Featured Image

Why is it important?

This study is important as it addresses the significant healthcare burden posed by chronic kidney disease (CKD) and highlights the critical need for effective management of drug-related problems (DRPs) in haemodialysis patients. By identifying the prevalence and types of DRPs in this population, the research underscores the importance of regular monitoring and multidisciplinary approaches to improve patient outcomes and quality of life. The findings have implications for healthcare providers in optimizing drug therapy regimens and reducing the incidence of DRPs, ultimately aiming to enhance the overall management of CKD on a global scale. Key Takeaways: 1. Prevalence of DRPs: The study reveals that 76.7% of haemodialysis patients experience drug-related problems, with drug interactions, adverse drug reactions, and failure to receive medication being the most common issues identified. 2. Impact of Medication Types: Phosphate binders, antihypertensive medicines, and PPIs/antacids are identified as the leading contributors to DRPs, emphasizing the need for careful selection and monitoring of these medications in haemodialysis patients. 3. Risk Factors for DRPs: Polypharmacy and comorbid conditions are significantly associated with increased odds of DRPs, highlighting the necessity for tailored therapeutic strategies and comprehensive care plans to mitigate these risks in haemodialysis patients.